SAN DIEGO, March 20, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the presentation of analytical and clinical data for its Target Selector™ liquid biopsy assay platforms at the GTCbio 11th Biomarker Summit being held March 27-28, 2018 in San Diego.
Tony J. Pircher, Ph.D., Biocept's Director of Immunochemistry, will serve as moderator for the Oncology Biomarker session. To begin the session, he will present "Utilizing Circulating Tumor Cells to Identify Predictive and Prognostic Biomarkers." Additionally, Biocept will present a poster at the conference entitled "Microfluidic Assay Detects dMMR in Circulating Tumor Cells (CTCs)."
"In these data sets, we demonstrate the ability of our circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) platforms to detect predictive and prognostic biomarkers from a simple blood sample, which can help physicians select personalized treatment regimens for their patients with cancer," said Dr. Pircher. "Our liquid biopsy assays can be particularly useful when there is insufficient sample material to perform a tissue biopsy or when a tissue biopsy has proven inadequate for identifying actionable biomarkers required to support the use of targeted drug therapy."
"We look forward to showcasing the capabilities of our liquid biopsy technology at this year's Biomarker Summit," stated Michael W. Nall, Biocept's President and CEO. "Our aim is to help physicians identify clinically actionable biomarkers as rapidly as possible with our Target Selector CTC and ctDNA platforms in order to enable timely and better informed treatment selection."
About Biomarker Summit 2018
Sponsored by GTCbio, Biomarker Summit 2018 is a meeting place for scientists and researchers to discuss all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an interactive environment with perspectives from industry, academia and the public.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-recent-advances-in-biomarker-identification-from-liquid-biopsies-at-gtcbios-11th-biomarker-summit-300616160.html